HALEOS LABS growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−3.2%+12.7%−3.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.8%+44.8%+8.2%
−2.8%+85.7%−10.0%
−5.0%+196.0%−44.4%
−13.9%+121.1%−20.7%
+16.5%−0.1%−1.1%
+8.3%+9.5%+2.9%
+9.3%+40.1%+65.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HALEOSLABS₹1,429.20

HALEOS LABS LIMITED

· Pharma & Health
₹ CrorePeersALBERTDAVDVALIANTLABMEDICOMEDICAMEQZIMLABAAREYDRUGSNECLIFEANUHPHRMcap ₹432 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-3.0+12.7-3.2—
EBITDA Growth—+8.2+44.8-0.8—
EBIT Growth—-10.0+85.7-2.8—
Net Income Growth—-44.4+196.0-5.0—
EPS Growth—-20.7+121.1-13.9—
Total Assets Growth—-1.1-0.1+16.5—
Total Equity Growth—+2.9+9.5+8.3—
Cash from Operations Growth—+65.4+40.1+9.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.